Research explained · Reviewed September 15, 2026
Cagrilintide brings another biological pathway into metabolic research: amylin signalling. Its development shows how studying complementary signals can open new possibilities for weight-management medicines.
Why amylin is an interesting target
Cagrilintide is a long-acting amylin analogue. Amylin is involved in the regulation of appetite and food intake, giving researchers a pathway to explore alongside GLP-1. The appeal of this approach is biological complementarity: different signals may contribute to the overall regulation of eating and body weight. Read the single-agent phase 2 trial.
Encouraging results with cagrilintide alone
A dose-finding trial published in 2021 randomized 706 adults with overweight or obesity across cagrilintide, liraglutide and placebo groups. Under its trial-product analysis, mean weight reductions across the cagrilintide groups ranged from 6.0% to 10.8%, compared with 3.0% with placebo. This provided a concrete human signal supporting further development. See the study methods and results.
A dose-finding study helps identify which exposures deserve closer investigation. Its average results describe the enrolled groups; they are not a forecast for every individual. The analysis method also matters: an estimate based on continued treatment answers a different question from an estimate that includes stopping treatment.
What combination research adds
The 2025 REDEFINE 1 publication reported results from 3,417 participants in a 68-week trial that included the combination, each individual component and placebo. Estimated mean weight change was −20.4% with cagrilintide–semaglutide and −3.0% with placebo. The study enrolled adults without diabetes who met its weight and health criteria. Read the phase 3 trial.
This is an important advance from mechanism to measured clinical outcomes. It also gives readers a practical way to interpret a headline: identify whether a number concerns cagrilintide alone or the combination. The combination result should not be assigned to the single ingredient.
Questions shaping the next stage
Useful comparisons include sustained outcomes, treatment completion, adverse effects and results in different populations. A separate phase 2 study examined the combination in adults with type 2 diabetes, illustrating how development can investigate more than one clinical setting. Explore that diabetes study.
The positive outlook is grounded in a growing body of controlled research. The most informative next results will show where this approach fits, for whom, and with what balance of benefits and tolerability. Clinical-trial combinations also have defined formulations; their results are not instructions for mixing unrelated research products.